First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial - Takeaways - MDSpire

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • By

  • Eusebio Luna Velasquez

  • Renil S. Titus

  • David-Dan Nguyen

  • Carlos Riveros

  • Aly-Khan Lalani

  • Dharam Kaushik

  • Guru P. Sonpavde

  • Petros Grivas

  • Christopher J. D. Wallis

  • Raj Satkunasivam

  • July 1, 2026

  • 0 min

Share

  • 1

    Metastatic urothelial carcinoma (mUC) has poor long-term survival, with first-line platinum-based chemotherapy yielding a median overall survival of approximately 15 months.

  • 2

    The phase 3 EV-302 trial demonstrated superior overall survival and progression-free survival with enfortumab vedotin plus pembrolizumab compared to platinum-based chemotherapy.

  • 3

    Enfortumab vedotin plus pembrolizumab received FDA approval as a first-line treatment for mUC in 2024 based on the findings from the EV-302 trial.

  • 4

    This retrospective cohort study utilized the TriNetX database to evaluate the effectiveness of enfortumab vedotin plus pembrolizumab in a broader mUC patient population.

  • 5

    The primary outcome of the study was overall survival, with secondary outcomes including treatment sequencing patterns and adverse events associated with the therapies.

Original Source(s)

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • by Eusebio Luna Velasquez, Renil S. Titus, David-Dan Nguyen, Carlos Riveros, Aly-Khan Lalani, Dharam Kaushik, Guru P. Sonpavde, Petros Grivas, Christopher J. D. Wallis, Raj Satkunasivam

  • July 1, 2026

Related Content

Radiomics-Based AI for the Diagnosis and Prognosis of Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min
Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report